{"id":1014068,"date":"2026-10-27T10:54:35","date_gmt":"2026-10-27T14:54:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/"},"modified":"2026-10-27T10:54:35","modified_gmt":"2026-10-27T14:54:35","slug":"pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/","title":{"rendered":"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, Oct.  27, 2026  (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC) at the 38<sup>th<\/sup> EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 &#8211; November 20, 2026.<\/p>\n<p>In addition, Pyxis Oncology will present two posters highlighting preclinical research involving MICVO during the symposium\u2019s antibody-drug conjugates session.<\/p>\n<p>\n        <strong>Oral Presentation Details:<\/strong>\n      <\/p>\n<p>\n        <strong>Title: <\/strong>Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)<br \/><strong>Presenter: <\/strong>Faye M. Johnson, M.D., Ph.D., The University of Texas MD Anderson Cancer Center<br \/><strong>Session: <\/strong>Proffered Papers: Clinical Trials <br \/><strong>Abstract number: <\/strong>3LBA<br \/><strong>Date and time: <\/strong>Thursday, November 19, 2026, from 10:00 a.m. &#8211; 11:30 a.m. CET <br \/><strong>Location: <\/strong>Room 111 + 112<\/p>\n<p>\n        <strong>Poster Presentation Details:<\/strong>\n      <\/p>\n<p>\n        <strong>Poster Title:<\/strong> In vitro characterization of the mechanism of action of micvotabart pelidotin, an antibody-drug conjugate targeting extradomain-B of fibronectin<br \/><strong>Session Title:<\/strong>\u202fAntibody-drug conjugates<br \/><strong>Session Day:<\/strong> Wednesday, November 18, 2026, from 12:00 p.m. &#8211; 7:00 p.m. CET<br \/><strong>Location:<\/strong>\u202fExhibition Hall<br \/><strong>Poster Board Number:<\/strong> PB-054<\/p>\n<p>\n        <strong>Poster Title:<\/strong> Micvotabart pelidotin in combination with EGFR-targeted therapy improves duration of response in HNSCC PDX models<br \/><strong>Session Title:<\/strong>\u202fAntibody-drug conjugates<br \/><strong>Session Day:<\/strong> Wednesday, November 18, 2026, from 12:00 p.m. &#8211; 7:00 p.m. CET<br \/><strong>Location:<\/strong>\u202fExhibition Hall<br \/><strong>Poster Board Number:<\/strong> PB-079<\/p>\n<p>\n        <strong>About Micvotabart Pelidotin (MICVO)<\/strong><br \/>\n        <br \/>Micvotabart pelidotin (MICVO, formerly PYX-201) is an antibody-drug conjugate (ADC) that uniquely targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extracellular matrix density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response.<\/p>\n<p>MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R\/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.<\/p>\n<p>\n        <strong>About Pyxis Oncology<\/strong><br \/>\n        <br \/>Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company\u2019s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R\/M HNSCC) and in combination with Merck\u2019s anti-PD-1 therapy, KEYTRUDA<sup>\u00ae<\/sup>\u00a0(pembrolizumab) in a Phase 1\/2 clinical study in patients with R\/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R\/M HNSCC and contributing to meaningful progress in cancer treatment.<\/p>\n<p>To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8e7J7EtQT11pr3fb1fTQlAMVpVEfIC8pa_vod7mIePXDa-P7-OH4QoSzOdQ1t6DpqTphDXUw_uypuv5QYjCze57cuDHHpZBqq_ljNRWxkCeQxjuGDGpKtQDT_2aQm5V36GTrwb8VnrNM0E6XON5jUNJAewlYxYYHRkhbrRqqCvouU-ELGbpZ9F2z3rZZkowftVAXejqRPJ5KWmXo0qYEqqLqlIGcBPc53Jp7y83OjwAYwU210cJaW8rqc188EPVyxV3DSdBffCCBBYbl5TtrxEnFSKXKakSCoOalZxXuOLPq_7eAz1jpz6ZZi5G8EQLIEvjeGToNuQo9-qW0dLf8q5_6LIBJzC4RpNeowa6FC5WLI2OezFAkLeYhzxFVKMNbZPfwlYYnbXOUqiiKcZ1eiHRa-COU0jyPB9-OLBY8PJJuBYopO6grM1YgU8GyMJctcaUg5OW-Z2oWq2L_Dp3juSfwQpf6-tX_n0pi2lYL7fCsiRxhOKLvvPklEJnrS3DM\" rel=\"nofollow\" target=\"_blank\">www.pyxisoncology.com<\/a>\u00a0or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HydEeg6oJZb9QqlGwGNkh3C3znJfEOcplGBOwhERLDHfcoUTNpRxaKX806sayDLreMynBrJ9Zi3sWCavCB5eQmW8G1TtI7DiFWHbVs7zQKU_YB8IuOGZ-1KNPx77OtA-U17hjPtAMiDxMYC6kNVaaJ5iQMxX1jp0UplKJMzzD7gDiov-9X98msAnV3yVNPdcmaqy-msN2--Lrzk2e7zCRN-GCrgpavJnds6RZb2Vy-OsODyBIsomtmru4Hm0sjddxwCdHx8DwNezUprVNfXRaS_eP0yqvmN-9pOL17zvNq3eidMgYhEGbY4UBgtxfSGUenaJbqGUls98sMlvH-ID5x-WkWrQUeXZSHXL-L90krjFTXBILOdnKiY8Aa1AG_s5VF1lBGy5kYw1dq6Fu45QSVOVHUzPLK7I_TTcd3LYhTPmeh0IBTQLzIZpndGENCLE\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>KEYTRUDA<sup>\u00ae<\/sup> is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.<\/p>\n<p>\n        <strong>Pyxis Oncology Contact<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-b50B7cshSy72V_JRbl1x0IrNLWcF5QqjtsSKzVgRWqktfqkxPSslYZLSrGQOJwTzLz2EQtcNMB-Ba-uHpk_1mUbFSinEIU6HZekh9MZhQ_WiWuCUvcS8k-yvQgVs_9-V3-CkRo54LLir9N5vw_1CNN6dvHkZ_LqeYMZV4La8b_NHsBXWGS7uNMhSfLze5KWC_Qux_O7hrEbKyqfmOKMWFnrJtTsigSj0jMkz3YPeNknKaes5dWVnYC8piFNubOhsjNczsGx_oqDZ-dSlbY2qA==\" rel=\"nofollow\" target=\"_blank\">IR@pyxisoncology.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDU3ODFmNTgtMmQ3Zi00NDQ2LTgxNDMtODU4YjIyOGE0OWZkLTEyMjA3ODItMjAyNi0xMC0yNy1lbg==\/tiny\/Pyxis-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 &#8211; November 20, 2026. In addition, Pyxis Oncology will present two posters highlighting preclinical research involving MICVO during the symposium\u2019s antibody-drug conjugates session. Oral Presentation Details: Title: Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)Presenter: Faye M. Johnson, M.D., Ph.D., The University of Texas MD &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1014068","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 &#8211; November 20, 2026. In addition, Pyxis Oncology will present two posters highlighting preclinical research involving MICVO during the symposium\u2019s antibody-drug conjugates session. Oral Presentation Details: Title: Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)Presenter: Faye M. Johnson, M.D., Ph.D., The University of Texas MD &hellip; Continue reading &quot;Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T14:54:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics\",\"datePublished\":\"2026-10-27T14:54:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/\"},\"wordCount\":567,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/\",\"name\":\"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=\",\"datePublished\":\"2026-10-27T14:54:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/","og_locale":"en_US","og_type":"article","og_title":"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Market Newsdesk","og_description":"BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC) at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 &#8211; November 20, 2026. In addition, Pyxis Oncology will present two posters highlighting preclinical research involving MICVO during the symposium\u2019s antibody-drug conjugates session. Oral Presentation Details: Title: Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)Presenter: Faye M. Johnson, M.D., Ph.D., The University of Texas MD &hellip; Continue reading \"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-27T14:54:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","datePublished":"2026-10-27T14:54:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/"},"wordCount":567,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/","name":"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=","datePublished":"2026-10-27T14:54:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MzkxOCM3OTE4Mzk3IzIyMDkyMjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-breaking-oral-presentation-and-two-poster-presentations-at-eortc-nci-aacr-symposium-on-molecular-targets-and-ca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1014068"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1014068\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1014068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1014068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1014068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}